Sanofi-aventis has acquired rights to Ascenta Therapeutics’ early-stage oral cancer drug candidates while its Sanofi Pasteur vaccine division has signed a partnership with the French biotech Vivalis for the development of human monoclonal antibodies against various infectious diseases.